Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA against NEDD9
- Development stage
- Preclinical
- Lead developer
- University of Maryland, Baltimore
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratracheal
01
Overview
siRNA against NEDD9 is an experimental small interfering RNA therapeutic designed to silence the expression of the NEDD9 protein. NEDD9 (Neural precursor cell expressed, developmentally down-regulated 9) is a scaffolding protein that has been identified as a regulator of fibrotic remodeling in the pulmonary vasculature of patients with pulmonary arterial hypertension (PAH). By knocking down NEDD9, the drug aims to reverse fibroproliferative remodeling, reduce extracellular matrix deposition (such as collagen III), and improve pulmonary hemodynamics. Research conducted at the University of Maryland, Baltimore, has demonstrated that intratracheal administration of siNEDD9 in experimental rat models of PAH significantly reduces right ventricular systolic pressure and vascular hypertrophy.
- Other names
- NEDD9 siRNANEDD-9 siRNANEDD 9 siRNA
02
Targets
NEDD9 (Neural precursor cell expressed, developmentally down-regulated protein 9)AGO2 (Argonaute RISC catalytic component 2)
Beyond the preview
Go deeper on siRNA against NEDD9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA against NEDD9.